Literature DB >> 18955708

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Andrew Y Choo1, Sang-Oh Yoon, Sang Gyun Kim, Philippe P Roux, John Blenis.   

Abstract

The mammalian translational initiation machinery is a tightly controlled system that is composed of eukaryotic initiation factors, and which controls the recruitment of ribosomes to mediate cap-dependent translation. Accordingly, the mTORC1 complex functionally controls this cap-dependent translation machinery through the phosphorylation of its downstream substrates 4E-BPs and S6Ks. It is generally accepted that rapamycin, a specific inhibitor of mTORC1, is a potent translational repressor. Here we report the unexpected discovery that rapamycin's ability to regulate cap-dependent translation varies significantly among cell types. We show that this effect is mechanistically caused by rapamycin's differential effect on 4E-BP1 versus S6Ks. While rapamycin potently inhibits S6K activity throughout the duration of treatment, 4E-BP1 recovers in phosphorylation within 6 h despite initial inhibition (1-3 h). This reemerged 4E-BP1 phosphorylation is rapamycin-resistant but still requires mTOR, Raptor, and mTORC1's activity. Therefore, these results explain how cap-dependent translation can be maintained in the presence of rapamycin. In addition, we have also defined the condition by which rapamycin can control cap-dependent translation in various cell types. Finally, we show that mTOR catalytic inhibitors are effective inhibitors of the rapamycin-resistant phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955708      PMCID: PMC2582304          DOI: 10.1073/pnas.0809136105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Internal ribosome entry sites in cellular mRNAs: mystery of their existence.

Authors:  Anton A Komar; Maria Hatzoglou
Journal:  J Biol Chem       Date:  2005-03-04       Impact factor: 5.157

2.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin.

Authors:  G J Brunn; C C Hudson; A Sekulić; J M Williams; H Hosoi; P J Houghton; J C Lawrence; R T Abraham
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

3.  Control of PHAS-I phosphorylation in 3T3-L1 adipocytes: effects of inhibiting protein phosphatases and the p70S6K signalling pathway.

Authors:  T A Lin; J C Lawrence
Journal:  Diabetologia       Date:  1997-07       Impact factor: 10.122

4.  4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway.

Authors:  A C Gingras; S G Kennedy; M A O'Leary; N Sonenberg; N Hay
Journal:  Genes Dev       Date:  1998-02-15       Impact factor: 11.361

5.  Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism.

Authors:  Victoria L Greenberg; Stephen G Zimmer
Journal:  Oncogene       Date:  2005-07-14       Impact factor: 9.867

6.  Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases.

Authors:  Brian Raught; Franck Peiretti; Anne-Claude Gingras; Mark Livingstone; David Shahbazian; Greg L Mayeur; Roberto D Polakiewicz; Nahum Sonenberg; John W B Hershey
Journal:  EMBO J       Date:  2004-04-08       Impact factor: 11.598

7.  Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.

Authors:  S Pyronnet; H Imataka; A C Gingras; R Fukunaga; T Hunter; N Sonenberg
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

Review 8.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

9.  Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation.

Authors:  L Beretta; A C Gingras; Y V Svitkin; M N Hall; N Sonenberg
Journal:  EMBO J       Date:  1996-02-01       Impact factor: 11.598

10.  mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E.

Authors:  A E Koromilas; A Lazaris-Karatzas; N Sonenberg
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  402 in total

1.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Authors:  Paige Yellen; Mahesh Saqcena; Darin Salloum; Jiangnan Feng; Angela Preda; Limei Xu; Vanessa Rodrik-Outmezguine; David A Foster
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

3.  mTOR links incretin signaling to HIF induction in pancreatic beta cells.

Authors:  Sam Van de Velde; Meghan F Hogan; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

4.  PI3K-mTORC1 attenuates stress response by inhibiting cap-independent Hsp70 translation.

Authors:  Jun Sun; Crystal S Conn; Yan Han; Vincent Yeung; Shu-Bing Qian
Journal:  J Biol Chem       Date:  2010-12-22       Impact factor: 5.157

5.  Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells.

Authors:  Yanyan Wang; Gonghua Huang; Hu Zeng; Kai Yang; Richard F Lamb; Hongbo Chi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

6.  eRapa restores a normal life span in a FAP mouse model.

Authors:  Paul Hasty; Carolina B Livi; Sherry G Dodds; Diane Jones; Randy Strong; Martin Javors; Kathleen E Fischer; Lauren Sloane; Kruthi Murthy; Gene Hubbard; Lishi Sun; Vincent Hurez; Tyler J Curiel; Zelton Dave Sharp
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-26

7.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

8.  Chemoproteomic Profiling Uncovers CDK4-Mediated Phosphorylation of the Translational Suppressor 4E-BP1.

Authors:  Dylan C Mitchell; Arya Menon; Amanda L Garner
Journal:  Cell Chem Biol       Date:  2019-05-02       Impact factor: 8.116

9.  Parallel measurement of dynamic changes in translation rates in single cells.

Authors:  Kyuho Han; Ariel Jaimovich; Gautam Dey; Davide Ruggero; Oded Meyuhas; Nahum Sonenberg; Tobias Meyer
Journal:  Nat Methods       Date:  2013-11-10       Impact factor: 28.547

10.  The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.

Authors:  Jennifer R Bean; Sarah R Hosford; Lynn K Symonds; Philip Owens; Lloye M Dillon; Wei Yang; Kevin Shee; Gary N Schwartz; Jonathan D Marotti; Kristen E Muller; Kari M Rosenkranz; Richard J Barth; Vivian S Chen; Veena R Agarwal; Todd W Miller
Journal:  Breast Cancer Res Treat       Date:  2014-12-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.